These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1992602)

  • 1. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
    Gaillard-Moguilewsky M
    Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
    Simard J; Singh SM; Labrie F
    Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action and pure antiandrogenic properties of flutamide.
    Labrie F
    Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
    Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
    Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects.
    Térouanne B; Tahiri B; Georget V; Belon C; Poujol N; Avances C; Orio F; Balaguer P; Sultan C
    Mol Cell Endocrinol; 2000 Feb; 160(1-2):39-49. PubMed ID: 10715537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
    Du Plessis DJ
    Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiandrogens. Mechanisms and paradoxical effects].
    Mowszowicz I
    Ann Endocrinol (Paris); 1989; 50(3):189-99. PubMed ID: 2530930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
    Steinsapir J; Mora G; Muldoon TG
    Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
    Moguilewsky M; Tournemine C
    Am J Clin Oncol; 1988; 11 Suppl 2():S148-51. PubMed ID: 3149454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
    Gillatt D
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.